TY - JOUR
T1 - A partially disordered region connects gene repression and activation functions of EZH2
AU - Jiao, Lianying
AU - Shubbar, Murtada
AU - Yang, Xin
AU - Zhang, Qi
AU - Chen, Siming
AU - Wu, Qiong
AU - Chen, Zhe
AU - Rizo, Josep
AU - Liu, Xin
N1 - Funding Information:
under contract DE-AC02-06CH11357. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US DOE under contract DE-AC02-05CH11231. Use of the Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory, is supported by the US DOE, Office of Science, Office of Basic Energy Sciences under Contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the NIH, National Institute of General Medical Sciences (NIGMS) (including P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. SAXS data were collected at SIBYLS beamline 12.3.1 at the ALS. SAXS data collection at SIBYLS is funded through the DOE Biological and Environmental Research Integrated Diffraction Analysis Technologies program and NIGMS grant P30 GM124169-01, ALS-ENABLE.
Funding Information:
We thank Dr. Jindan Yu from Northwestern University for providing the AR promoter-containing reporter gene plasmids and for the discussion of gene expression analysis in prostate cancer cells. We thank Dr. Laura Banaszynski from University of Texas (UT) Southwestern Medical Center for providing the plasmid for transient expression of p300. This research was supported by Welch Foundation research grant I-1790 to X.L. and I-1304 to J.R. and Cancer Prevention and Research Institute of Texas research grant R1119, Rita Allen Foundation research grant, UT Southwestern Medical Center Endowed Scholar fund, and NIH grants GM114576, GM121662, and GM136308 to X.L. L.J. was supported by American Heart Association postdoctoral fellowship 16POST30700004. X.L. is a W. W. Caruth, Jr. Scholar in Biomedical Research. This research also received support from the Cecil H. and Ida Green Center Training Program in Reproductive Biology Sciences Research. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract DE-AC02-06CH11357. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US DOE under contract DE-AC02-05CH11231. Use of the Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory, is supported by the US DOE, Office of Science, Office of Basic Energy Sciences under Contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the NIH, National Institute of General Medical Sciences (NIGMS) (including P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. SAXS data were collected at SIBYLS beamline 12.3.1 at the ALS. SAXS data collection at SIBYLS is funded through the DOE Biological and Environmental Research Integrated Diffraction Analysis Technologies program and NIGMS grant P30 GM124169-01, ALS-ENABLE.
Funding Information:
ACKNOWLEDGMENTS. We thank Dr. Jindan Yu from Northwestern University for providing the AR promoter-containing reporter gene plasmids and for the discussion of gene expression analysis in prostate cancer cells. We thank Dr. Laura Banaszynski from University of Texas (UT) Southwestern Medical Center for providing the plasmid for transient expression of p300. This research was supported by Welch Foundation research grant I-1790 to X.L. and I-1304 to J.R. and Cancer Prevention and Research Institute of Texas research grant R1119, Rita Allen Foundation research grant, UT Southwestern Medical Center Endowed Scholar fund, and NIH grants GM114576, GM121662, and GM136308 to X.L. L.J. was supported by American Heart Association postdoctoral fellowship 16POST30700004. X.L. is a W. W. Caruth, Jr. Scholar in Biomedical Research. This research also received support from the Cecil H. and Ida Green Center Training Program in Reproductive Biology Sciences Research. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory
Publisher Copyright:
© 2020 National Academy of Sciences. All rights reserved.
PY - 2020/7/21
Y1 - 2020/7/21
N2 - Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which minimally requires two other subunits, EED and SUZ12, for enzymatic activity. EZH2 has been traditionally known to mediate histone H3K27 trimethylation, a hallmark of silent chromatin. Emerging evidence indicates that EZH2 also activates gene expression in cancer cells in a context distinct from canonical PRC2. The molecular mechanism underlying the functional conversion of EZH2 from a gene repressor to an activator is unclear. Here, we show that EZH2 harbors a hidden, partially disordered transactivation domain (TAD) capable of interacting with components of active transcription machinery, mimicking archetypal acidic activators. The EZH2 TAD comprises the SRM (Stimulation-Responsive Motif) and SANT1 (SWI3, ADA2, N-CoR, and TFIIIB 1) regions that are normally involved in H3K27 methylation. The crystal structure of an EZH2−EED binary complex indicates that the EZH2 TAD mediates protein oligomerization in a noncanonical PRC2 context and is entirely sequestered. The EZH2 TAD can be unlocked by cancer-specific EZH2 phosphorylation events to undergo structural transitions that may enable subsequent transcriptional coactivator binding. The EZH2 TAD directly interacts with the transcriptional coactivator and histone acetyltransferase p300 and activates gene expression in a p300-dependent manner in cells. The corresponding TAD may also account for the gene activation function of EZH1, the paralog of EZH2. Distinct kinase signaling pathways that are known to abnormally convert EZH2 into a gene activator in cancer cells can now be understood in a common structural context of the EZH2 TAD.
AB - Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which minimally requires two other subunits, EED and SUZ12, for enzymatic activity. EZH2 has been traditionally known to mediate histone H3K27 trimethylation, a hallmark of silent chromatin. Emerging evidence indicates that EZH2 also activates gene expression in cancer cells in a context distinct from canonical PRC2. The molecular mechanism underlying the functional conversion of EZH2 from a gene repressor to an activator is unclear. Here, we show that EZH2 harbors a hidden, partially disordered transactivation domain (TAD) capable of interacting with components of active transcription machinery, mimicking archetypal acidic activators. The EZH2 TAD comprises the SRM (Stimulation-Responsive Motif) and SANT1 (SWI3, ADA2, N-CoR, and TFIIIB 1) regions that are normally involved in H3K27 methylation. The crystal structure of an EZH2−EED binary complex indicates that the EZH2 TAD mediates protein oligomerization in a noncanonical PRC2 context and is entirely sequestered. The EZH2 TAD can be unlocked by cancer-specific EZH2 phosphorylation events to undergo structural transitions that may enable subsequent transcriptional coactivator binding. The EZH2 TAD directly interacts with the transcriptional coactivator and histone acetyltransferase p300 and activates gene expression in a p300-dependent manner in cells. The corresponding TAD may also account for the gene activation function of EZH1, the paralog of EZH2. Distinct kinase signaling pathways that are known to abnormally convert EZH2 into a gene activator in cancer cells can now be understood in a common structural context of the EZH2 TAD.
KW - EZH2
KW - Gene activation
KW - Phosphorylation
KW - Transcriptional activation domain
KW - p300
UR - http://www.scopus.com/inward/record.url?scp=85088880925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088880925&partnerID=8YFLogxK
U2 - 10.1073/pnas.1914866117
DO - 10.1073/pnas.1914866117
M3 - Article
C2 - 32631994
AN - SCOPUS:85088880925
SN - 0027-8424
VL - 117
SP - 16992
EP - 17002
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 29
ER -